Cholecystokinin (CCK) is an important hormonal regulator of the digestive process. CCK cells are concentrated in the proximal small intestine, and hormone is secreted into the blood upon the ingestion of food. The physiological actions of CCK include stimulation of pancreatic secretion and gallbladder contraction, regulation of gastric emptying, and induction of satiety. Therefore, in a highly coordinated manner, CCK regulates the ingestion, digestion, and absorption of nutrients. CCK is produced by two separate cell types: endocrine cells of the small intestine and various neurons in the gastrointestinal tract and central nervous system. Accordingly, CCK can function as either a hormone or a neuropeptide. This review focuses on the physiology of the CCK cell in the intestine and, in particular, on how the CCK cell is regulated to secrete its hormone product. The effects of ingested nutrients on the CCK cell and the intracellular messenger systems involved in controlling secretion are reviewed. A summary is provided of recent studies examining the electrophysiological properties of CCK cells and newly discovered proteins that act as releasing factors for CCK, which mediate feedback pathways critical for regulated secretion in the intact organism.
Introduction
Cholecystokinin (CCK) was discovered in 1928 by Ivy & Oldberg based on the ability of intestinal extracts to stimulate gallbladder contraction when infused into dogs (1) . In 1943, Harper & Raper recognized that similar intestinal extracts also stimulated pancreatic enzyme secretion and proposed the name pancreozymin (2) . It was not until the active substance was purified and the amino acid sequence determined that CCK and pancreozymin were proven to be the same hormone that now goes by the name cholecystokinin (3) .
In addition to the two biological actions described above, CCK has several other important activities. Among the most notable is its ability to induce 221 0066-4278/97/0315-0221$08.00 satiety and reduce food intake in experimental animals and humans (4) (5) (6) . It also inhibits gastric emptying and gastric acid secretion and stimulates intestinal peristalsis. Defining the physiological actions of CCK has been greatly facilitated by the development of specific and potent antagonists of the CCK-A (A for alimentary origin) receptor. Each of the above actions ascribed to CCK arises from endogenous CCK, as shown in studies by which the response to a normal meal can be reversed by specific CCK-A receptor antagonists.
CCK release is stimulated by ingestion of food, with fats and protein the most potent secretagogues. CCK secretion is initiated when food leaves the stomach and enters the small intestine, and secretion continues until proteins, fats, and their metabolites have passed the upper small intestine.
CCK receptors have been identified on the gallbladder, pancreas, and stomach (7) . Recent evidence indicates that specific CCK-A receptors are also present on peripheral autonomic afferent nerves that enable CCK to initiate certain neural reflexes. The specific site on which CCK acts to affect organ responses is still somewhat unclear. The best evidence for a purely endocrine role for CCK is regulation of gallbladder contraction, whereas other effects may be either neural or a combination of endocrine and neural actions. Nevertheless, the importance of CCK in regulating a variety of digestive processes must not be underestimated. CCK secreted locally or into the blood binds to specific receptors on the gallbladder, pancreas, stomach, or various nerves to stimulate gallbladder contraction, pancreatic enzyme secretion, delay gastric emptying, and regulate satiety (7) . Therefore, in a highly regulated fashion, CCK coordinates the ingestion, digestion, and disposal of nutrients (8, 9) .
Peptide Structure
CCK was originally purified from porcine intestine as a 33-amino acid peptide (3) . The hormone possesses an amidated carboxy-terminal pentapeptide, Gly-Trp-Asp-Met-Phe-NH 2 , that is identical to that of gastrin. The carboxyl terminus of CCK is the biologically active portion of the hormone, and because of sequence similarity between CCK and gastrin, each hormone can interact with the receptor of the other (see receptor characterization below). Therefore, gastrin has slight CCK-like bioactivity and CCK possesses some, albeit weak, gastrin-like activity. The homology shared by the two peptides explains why antibodies raised against CCK often cross-react with gastrin. This overlapping cross-reactivity has been a considerable problem in developing radioimmunoassays for CCK, particularly because gastrin circulates in the blood at concentrations 10-100 times greater than those of CCK (10) .
Since the discovery of CCK, multiple molecular forms have been identified in intestine, brain, and the circulation of multiple species (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The octapeptide of CCK (CCK-8), consisting of the carboxy-terminal 8 amino acids of CCK, is the most biologically potent small peptide of CCK that has been isolated. However, amino-terminal extended forms have been extracted from brain and intestine of the pig, dog, rat, and human. Using techniques to minimize protein degradation, recent studies have demonstrated that the most abundant molecular form of CCK in these species is CCK-58. Intermediate-sized peptides of 39, 33, 25, 22, 18, 8, 7, 5 , and 4 amino acids have been isolated from several species.
CCK Gene Structure and Expression
The complementary DNA structures have been determined for rat, mouse, pig, and human CCK (21) (22) (23) (24) . The structure of the rat cDNA is shown schematically in Figure 1 . The 345-nucleotide mRNA encodes a 115-amino acid precursor consisting of a 20-amino acid signal peptide, a 25-amino acid spacer peptide, CCK-58, and a 12-amino acid extension at the carboxyl terminus.
The genes for CCK isolated for mouse, rat, and human reveal remarkable conservation (22) (23) (24) (25) . Each consists of ∼7 kilobases containing three exons, the second and third of which encode the prepropeptide. In all species, only a single gene encodes CCK. The human CCK gene is located on chromosome 3 in the 3q12-3pter region (26, 27) .
The mature CCK mRNA is ∼750 bases. It is expressed in brain and intestine in mature animals in nearly equivalent amounts. CCK mRNA is most abundant in the cerebral cortex and duodenum. In the mouse, at birth, CCK mRNA levels are relatively high in the intestine but very low in brain. Over the first two weeks of life, levels decrease in the gut and increase in brain. These changes correlate with levels of immunoreactive CCK protein in the respective tissues. Intestinal expression of CCK mRNA is modified by diet. CCK mRNA levels decline in either fasting rats or rats fed a diet that does not stimulate CCK secretion (28) . CCK mRNA expression increases with feeding under conditions that also stimulate CCK secretion. However, it is possible to stimulate CCK secretion without affecting CCK gene expression by administration of exogenous bombesin (29) . Somatostatin has been shown to inhibit CCK gene expression (30) .
Structure-Activity Relationships
To function as a CCK molecule, a peptide must have the sequence Trp-AspMet-Phe-NH 2 . However, because this sequence is identical to the the carboxyl terminus of gastrin, this peptide does not confer CCK-like specificity. In order to bind specifically to CCK receptors, CCK peptides must be extended to 7 amino acids. Full potency is not achieved unless the tyrosine residue at position 7 from the carboxyl terminus is sulfated (31) . Although sulfation is unusual for hormones, it is critical for biological potency of CCKs. The unsulfated form of CCK is ∼1000-fold less active than its sulfated counterpart. In contrast, sulfation occurs only 50% of the time in gastrin biosynthesis and is not important for its biological activity.
Molecular forms ranging in size from CCK-8 to CCK-33 appear to be of similar biological potency on pancreatic acinar cells (32) . However, CCK-58 is somewhat less potent on a molar basis than CCK-8 and is less immunoreactive with CCK antibodies (33) . This diminished activity is likely due to the structure of CCK-58, whereby the amino-terminal end shields the biologically active carboxy-terminal end of CCK from interacting with CCK receptors or C-terminal directed antibodies. Cleavage of CCK-58 with trypsin restores both the full biological potency and immunoreactivity to that of CCK-8 (34) . Although CCK-58 is the major molecular form in intestine, brain, and the circulation of many species, identification of multiple smaller forms of CCK in circulation, even under conditions that preserve CCK-58, suggests that intracellular processing of CCK occurs to produce small forms of CCK that are secreted into the blood.
CCK Receptors
CCK exerts its biological effects by binding to specific receptors on its target tissues. Originally receptors were characterized on pancreatic acinar cells, islets, gallbladder, and brain by radioligand binding and autoradiography (31) . In the pancreas and gallbladder, CCK bound with an affinity that was ∼1,000-fold greater than that of either unsulfated CCK or gastrin. These receptors were termed CCK-A. In the brain, however, CCK and gastrin bound with similar affinities. These receptors became known as CCK-B (B for brain origin). Along with these two types of CCK receptors, a third related type, "gastrin receptor," which exhibited binding properties similar to those of the brain CCK receptor, was believed to transmit the biological actions of gastrin in the stomach. However, with recent cloning and expression of the CCK receptor cDNAs, it has become clear that there are only two CCK receptors, A and B, and that the gastrin receptor is identical to the CCK-B receptor.
The CCK-A receptor complementary DNA was cloned following purification of the receptor protein from rat pancreatic acinar cells (35) . The cDNA encodes a seven transmembrane protein typical of G protein-coupled receptors. It consists of 444 amino acids, which when expressed in transfected cells, demonstrates high affinity for sulfated CCK and much lower affinity for unsulfated CCK or gastrin.
The CCK-B receptor cDNA was identified by expression cloning from canine gastric parietal cells (36) . When expressed in transfected cells, the CCK-B receptor binds CCK and gastrin with similar affinities and demonstrates a ligand-induced increase in intracellular calcium. When the cDNAs for the rat and human receptors were cloned, it was demonstrated that CCK receptor cloned from brain was identical to the gastrin receptor in the stomach (37) . The deduced amino acid sequences of the rat CCK-A and canine CCK-B receptors are ∼50% homologous.
CCK Cells
As is typical of many gastrointestinal hormones, CCK is produced by endocrine cells of the intestinal mucosa, which are concentrated in the duodenum and proximal jejunum. A gradient of cell density exists such that CCK cell abundance is greatest in the proximal small intestine and less in the distal intestine. Endocrine cells containing CCK are flask-shaped, with their apical surfaces oriented toward the lumen of the gut (38, 39) (Figure 2 ). In this position, microvillus-like processes come in contact with lumenal contents. Secretory granules, which are ∼250 nm in size and contain CCK, are concentrated around the basolateral surface of the cell. It is this orientation that allows food or other factors within the intestinal lumen to interact with the apical surface of the CCK cell and initiate a series of as yet unknown intracellular signaling events that ultimately result in secretion of CCK from the basal surface of the cell into the blood. According to the Wiesbaden classification, CCK cells, by their ultrastructural characteristics, have been officially named I cells (40) . Where examined in experimental animals or humans, I cells have not been shown to contain other gut hormones. Outside of the intestinal tract, CCK is synthesized by a subpopulation of pituitary and adrenal meduallary cells (41, 42) . The function of CCK in these locations is unknown. CCK is expressed in neurons of the brain and gut and as such is a member of the growing family of "brain-gut peptides." In the central nervous system, CCK is distributed in neurons throughout the brain. It is found in highest concentrations in the cerebral cortex (43, 44) . CCK cell bodies are localized in layers II-VI and concentrated in layers II and III. In the brain, CCK is colocalized with dopamine in neurons that arise in the mesencephalon and project to the limbic forebrain. CCK neurons also project to the ventromedial hypothalamus, which may be important for central effects of CCK in the regulation of satiety.
In the peripheral autonomic nervous system, CCK-containing neurons are found in the myenteric plexus, submucous plexus, circular muscle layers of the distal small intestine and colon, in the pancreas surrounding the islets of Langerhans, and in the celiac plexus and vagus nerve (45) . In the intestine, CCK stimulates release of acetylcholine in postganglionic neurons of Auerbach's and Meissner's plexi and causes smooth muscle contraction. Because CCK stimulates glucagon and insulin release, it is likely that postganglionic cells terminating around islets of Langerhans play a role in modifying α and β cell function (46) .
CCK Release
With the development of sensitive and specific radioimmunoassays and bioassays for measuring blood levels of CCK, there is now general agreement that fasting levels of CCK in most mammals are ∼1 pM and increase to ∼5-10 pM following strong endogenous stimulation (12, (47) (48) (49) (50) .
CCK release is stimulated by ingestion of food. Before the development of specific in vitro assays for measuring blood levels of CCK, estimates of CCK release were made by inference from examination of target tissue responses such as pancreatic secretion or gallbladder contraction. Although it was not possible to distinguish between hormonal and neural influences, substantial insights were gained about the food components that stimulate pancreactic secretion. Digestion products of fat and protein were found to be the most potent stimulants of secretion (51) . Effective stimulation required that triglycerides were hydrolyzed to fatty acids, with chain lengths of 9 or more carbons (52, 53) . However, it is important to recognize that not all effects on pancreatic secretion are attributable to circulating CCK because other hormones or neural CCK also may be involved (54) .
In most species, for protein to be an effective stimulant of CCK release, its digestion is required to effectively stimulate pancreatic secretion or gallbladder contraction (55) (56) (57) . Of the amino acids, tryptophan and phenylalanine are the most potent stimulants of canine or human pancreatic secretion. Secretion is most vigorous when the proximal (relative to the distal) half of the small intestine is perfused with nutrients. This finding is consistent with the abundance of CCK cells in the proximal intestine.
In the rat, intact protein is an effective stimulant of CCK release. This is likely due to the ability of protein to preserve the activity of an endogenously produced CCK-releasing factor that is active in the intestinal lumen to modulate CCK secretion (58) . Although this regulatory system has been best studied in the rat, it is also present in other species. Regulation of CCK secretion by releasing factors is discussed in more detail below.
The effects of neural factors on CCK secretion have been a matter of controversy but clarified somewhat by the application of specific CCK radioimmunoassays. Although the neuropeptide bombesin is known to affect pancreatic secretion through bombesin receptors on pancreatic acini, only recently has it been shown to directly stimulate CCK release (59) .
Vagotomy alters pancreatic and gallbladder responses to dietary stimulation. Therefore, indirect estimates of CCK secretion in vagotomized animals have been limited because the responsiveness of the pancreas or gallbladder could be the result of either changes in CCK release or the effects of vagotomy. Studies using radioimmunoassay measurements have shown that circulating CCK levels were unaltered in dogs administered oleate, despite impaired pancreatic and gallbladder responses (60) . In vagotomized subjects, plasma CCK responses were greater following a liquid meal, perhaps because of a more rapid delivery of nutrients to the small intestine following vagotomy (61) . In sum, these experiments suggest that vagal innervation does not affect CCK directly, but may alter the target tissue responses to stimulation by CCK.
Regulation of CCK Secretion by Releasing Factors
The exact mechanisms by which foods cause CCK secretion have yet to be elucidated, but it is likely that multiple factors are involved. The location of the CCK cell in the intestinal mucosa, with its apical surface exposed to the lumen of the gut, provides an opportunity for foods or other factors to interact directly with the CCK cell to stimulate hormone secretion. However, it is not known if food directly interacts with CCK cells to stimulate secretion. Substantial evidence has indicated that at least one mechanism causing CCK release involves endogenously produced releasing factors that are secreted into the lumen of the intestine and under the proper conditions stimulate CCK secretion (62, 63) . The rationale for their existence and description of at least two types of CCK-releasing factors are summarized below.
Experiments in rats in the 1970s demonstrated that inactivation or removal of proteolytic activity from the proximal small intestine by either instillation of trypsin inhibitors or diversion of bile-pancreatic juice from the intestine produced a large increase in pancreatic exocrine secretion (64) . In addition, intraduodenal infusion of trypsin in the absence of bile-pancreatic juice in the intestine suppressed pancreatic enzyme secretion (65) . These observations suggested that a negative feedback mechanism existed whereby pancreatic secretion was controlled by the presence or absence of protease activity within the lumen of the small intestine.
This concept has been used to explain how dietary proteins stimulate pancreatic secretion. In rats, intact proteins are more potent stimulants of CCK release than hydrolyzed proteins or amino acids, suggesting that the ability of dietary protein to stimulate the pancreas is related to its ability to serve as a proteolytic substrate (66) . In this regard, dietary proteins are similar to trypsin inhibitors when instilled into the gut because they both bind trypsin and cause pancreatic secretion.
It was proposed that a trypsin-sensitive releasing factor is secreted into the lumen of the intestine and stimulates CCK release (67) . In the presence of active proteases such as trypsin, this releasing factor would be degraded. However, when other proteins or potential substrates for trypsin are present in the gut (such as after eating a meal), the putative releasing factor would be protected and able to interact with CCK-secreting cells of the intestine (Figure 3) . There is now strong evidence that a feedback mechanism exists in the chicken, pig, rat, and human, and probably is present in the dog (64, (68) (69) (70) (71) (72) (73) (74) (75) (76) . In humans, intraduodenal perfusion of phenylalanine not only stimulates pancreatic secretion, but also CCK release; these effects are blocked by simultaneous infusion of trypsin, indicating that negative feedback regulation of CCK is important in this species (77) .
The mechanisms regulating the production and secretion of an intestinal CCK-releasing factor are largely unknown. It is controversial whether cholinergic innervation is important for secretion of the releasing peptide. In anesthetized rats, atropine prevents the spontaneous increase in pancreatic secretion caused by diversion of bile-pancreatic juice (78); however, in other studies in conscious rats, atropine has no effect on the increase in pancreatic secretion stimulated by intraduodenal infusion of either dietary protein or trypsin inhibitors (79, 80) or on plasma CCK levels that are appropriately elevated in atropine-treated, conscious rats following bile-pancreatic juice diversion (81) .
Therefore, a precise role for cholinergic regulation of CCK-releasing factor secretion remains to be established. It has been demonstrated recently that somatostatin inhibits the elevation in plasma CCK levels normally seen in bilepancreatic juice-diverted rats by inhibiting the release of a CCK-releasing factor (82) .
Regulation of a CCK-releasing factor may also differ among species. In humans, it is postulated that lumenal stimulation by nutrients such as amino acids or fatty acids is necessary to stimulate secretion of the putative CCKreleasing factor (69, 83, 84) . This situation differs from the rat, in which spontaneous secretion of CCK-releasing factor occurs and maximal CCK and pancreatic secretion result from removing proteases from the proximal intestine.
Very recently, two putative CCK-releasing factors have been chemically characterized. A novel 8169-kDa protein called lumenal cholecystokinin-releasing factor (LCRF) was purified from rat pancreatic juice (85) . LCRF stimulates pancreatic secretion and CCK release when instilled into the intestine. Moreover, this increase in CCK release is blocked by immunoneutralization with LCRFspecific antisera. It is possible that diazepam-binding inhibitor (DBI), which when extracted from porcine intestine was found to possess CCK-releasing activity, is a second CCK-releasing peptide (86) . The relative contributions of LCRF and DBI to regulation of CCK secretion following ingestion of a meal remain to be determined.
Characterization of a CCK-Releasing Factor from Pancreatic Juice: Monitor Peptide
In 1986, a 61-amino acid protein purified from pancreatic juice was found to stimulate CCK secretion when introduced into the lumen of rat intestine (87). This protein was named monitor peptide for its ability to monitor the intraduodenal environment for protein digestion (88, 89) . Because of its similarity to other pancreatic trypsin inhibitors, monitor peptide is also known as pancreatic secretory trypsin inhibitor-I (PSTI-61); it is distinct from a 56-amino acid pancreatic trypsin inhibitor known as PSTI-II (PSTI-56) that shares 66% sequence homology with monitor peptide but does not stimulate intestinal CCK release and pancreatic secretion (90) .
Monitor peptide is produced by pancreatic acinar cells and is secreted into pancreatic juice where, upon reaching the intestine, it stimulates CCK release. This mechanism for stimulating the CCK cell requires some level of pancreatic secretion to be effective. Therefore, once pancreatic secretion has been initiated, monitor peptide in pancreatic juice would tend to reinforce or perpetuate further secretion via release of CCK. In contrast, intestinal CCK-releasing factors differ from monitor peptide because they are of intestinal rather than pancreatic origin and are present in the gut under basal conditions (91) . Lumenal-releasing factors are believed to mediate much of the CCK secretion that results from nutrient ingestion, although it is clear that multiple mechanisms exist to ensure proper regulation of CCK release.
In isolated rat intestinal mucosal cells, monitor peptide stimulates CCK release in a concentration-and calcium-dependent manner, suggesting that monitor peptide has a direct effect on CCK cells and that calcium may serve as an intracellular messenger in monitor peptide-mediated CCK secretion (92) . The ability of monitor peptide to elevate [Ca 2+ ] i and stimulate CCK secretion has been used to enrich CCK cells from the intestine by fluorescence-activated cell sorting (93) . Enriched CCK cells respond to stimulation by monitor peptide, dibutyryl cAMP, membrane depolarizing concentrations of potassium chloride, and calcium ionophore.
A putative cell surface receptor that binds monitor peptide has been partially characterized in intestinal mucosal cells of the rat jejunum (94) . Autoradiography of an affinity cross-linked complex of 125 I-labeled monitor peptide and its binding site identified a potential receptor with a molecular mass of 33 or 53 kDa in its reduced or nonreduced form, respectively, providing evidence that monitor peptide binds directly to receptors on enteric cells of the small intestine. A proposed scheme for the regulation of CCK by the two classes of lumenal-releasing factors is shown in Figure 4 .
Cellular Regulation of CCK Secretion
The precise signaling pathways involved with CCK secretion are unknown. Studies in isolated canine intestinal mucosal cells enriched in CCK demonstrated that forskolin and cAMP analogues stimulate CCK release (95, 96) . Moreover, forskolin-activated secretion was blocked by somatostatin. Stimulation of protein kinase C (PKC) by the phorbol ester, β-phorbol-12-myristate-13-acetate (PMA), also caused significant CCK secretion, as did exposure to L-phenylalanine.
Recent investigations using the intestinal CCK-containing cell line STC-1 have been useful for examining the receptors on CCK cells and the potential second messenger pathways involved in regulating secretion. The bombesin family of neuropeptides, including gastrin-releasing peptide (GRP), have potent CCK stimulatory effects in animals (29, (97) (98) (99) and in organ preparations (100) . Although presumed to be a direct effect, the identification of GRP receptors in CCK-secreting cells (by radioligand binding and mRNA analysis) established that CCK cells possess bombesin-like receptors (101) . As a G protein-coupled receptor that couples to and signals through the phosphoinositide cascade, generating inositol trisphosphate (IP 3 by exposure to calcium-free media or treatment with L-type calcium channel blockers (59) .
Although maneuvers that increase intracellular cAMP have been shown to stimulate CCK release, little is known about the mechanisms for increasing cAMP levels in CCK cells. It was recently demonstrated, using STC-1 cells, that β-adrenergic receptors on CCK cells effectively coupled to the production of cAMP, resulting in CCK release (102) . Interestingly, the β-adrenergic agonist isoproterenol increased [Ca 2+ ] i , coincident with stimulating hormone secretion. Both CCK secretion and the elevation in [Ca 2+ ] i were reduced by treatment with the L-type calcium channel blocker diltiazem, indicating that β receptors on CCK cells are coupled to the production of cAMP, which may stimulate CCK release through a calcium-dependent process.
The manner by which dietary stimulants affect CCK secretion are largely unknown. A study of isolated intestinal cells in vitro indicates that dietary proteins which cause CCK release in animals do not have stimulatory effects in perfusion models (103) . These findings are consistent with the proposal that effects of protein on CCK release are mediated by an intestinal-releasing factor. However, in native CCK cells and STC-1 cells, L-phenylalanine stimulated CCK release and increased cytosolic calcium levels (in a dose-dependent manner) (104) . Both effects were blocked by diltiazem, indicating that phenylalanine stimulates release of CCK by a calcium-dependent process involving a calcium influx pathway in the cell.
The results of these experiments emphasize that influx of extracellular calcium from outside to inside the cell is a common feature of CCK secretion initiated by a variety of mechanisms. The critical role of [Ca 2+ ] i seems to apply whether the inciting event is due to monitor peptide, bombesin, isoproterenol, or phenylalanine stimulation. The relationship between intracellular cAMP and calcium signaling pathways becomes more apparent when it is observed that phosphodiesterase inhibitor IBMX not only stimulates CCK release in STC-1 cells, but also increases cytosolic calcium (105) . Moreover, the calciumcalmodulin kinase II inhibitor KN-62 markedly reduces IBMX-stimulated secretion and [Ca 2+ ] i , suggesting that cAMP may activate diltiazem-sensitive calcium channels by a calmodulin-dependent process. This conclusion is supported by the finding that the stimulatory effects of forskolin on CCK release are similarly blocked by . These studies provide evidence that both the adenylyl cyclase and phosphoinositide signaling cascades are active in CCK cells and may be coupled to ligand occupation of cell surface receptors to initiate intracellular events leading to CCK secretion (Figure 4) . The two signaling cascades are linked by calcium-calmodulin kinase II activity and regulation of intracellular calcium concentration.
Role of Ion Channels in CCK Secretion
In many endocrine cells, hormone secretion is coupled to changes in ion channel activity. One of the most apparent relationships is the dependence upon plasma membrane potential. Secretion of insulin, thyrotropin, growth hormone, prolactin, calcitonin, secretin, somatostatin, and cholecystokinin are all induced by solutions containing high potassium concentrations, indicating that the resting potential of these secretory cells is at least partially determined by the activity of potassium channels (107) (108) (109) (110) (111) .
Models for studying ion channel activity and endocrine secretion have included tissue preparations, dispersed cells, and clonal populations of cells. CCK cells are found scattered in the intestinal mucosa, making it difficult to obtain a uniform population of purified or enriched endocrine cells. Recently, an intestinal CCK-producing cell line (STC-1) was developed that secretes several gastrointestinal hormones, of which CCK is the most abundant (112, 113) . STC-1 cells have been used as a model for intestinal CCK secretion because identical stimuli release CCK from dispersed native intestinal cells and STC-1 cells (105, 111, (114) (115) (116) . Electrophysiological studies have been performed using STC-1 cells, which provide insight into the signal transduction pathways that are linked to ion channel activity and CCK secretion.
Initial patch-clamp recordings from STC-1 cells revealed an outwardly rectifying, calcium-independent, basal whole-cell current that was largely attributable to potassium channel activity (111) . The current reversal potential was −27 ± 3 mV in studies where the only ionic species with a negative reversal potential was potassium. The potassium channel blocker BaCl 2 rapidly depolarized the reversal potential toward 0 mV and decreased the magnitude of whole-cell current, which was consistent with potassium channel activity playing a predominant role in regulating membrane potential.
At least three types of potassium currents have been identified in STC-1 cells (111, (114) (115) (116) . One potassium channel is calcium dependent and is activated by secretagogues such as bombesin or thapsigargin that increase intracellular calcium (59, 111) . A second potassium current is inwardly rectifying and is inhibited by elevation of cytoplasmic ATP levels. Exposure of the cytoplasmic surface of inside-out membrane patches to ATP has been shown to close this K ATP channel. In addition, the open probability of the K ATP channel was found to be voltage independent. These studies raise the possibility that metabolic processes that significantly alter intracellular ATP concentrations may affect total potassium permeability and membrane potential. Interestingly, glucose has been shown to stimulate CCK release both in vivo and in isolated cell preparations and has significant inhibitory effects on K ATP channel activity (115, 117) . In STC-1 cells, glucose and the K ATP channel inhibitor disopyramide inhibit basal K + channel activity as measured by 86 Rb efflux experiments (115) . These studies demonstrate that K ATP channels are open under basal conditions and contribute to the resting membrane potential. Exposure to increased extracellular glucose concentrations closes K ATP channels and causes membrane depolarization. In both native mouse intestinal CCK cells and STC-1 cells, glucose and disopyramide stimulate CCK release, effects that are blocked by the L-type calcium channel blocker diltiazem. Therefore, it appears that K ATP channels are important contributors to the basal membrane potential in CCK-secreting cells and that inhibition of K ATP channels depolarizes the plasma membrane, causing activation of L-type calcium channels that leads to an increase in [Ca 2+ ] i , ultimately producing CCK secretion.
In some species, amino acids are potent stimulants of CCK secretion (12) . In particular, tryptophan and phenylalanine produce marked elevation in circulating CCK levels when they are administered into the stomach or duodenum. However, it is not known how amino acids actually affect the CCK cell to stimulate secretion. In vitro, phenylalanine exposure to STC-1 cells causes hormone release (104, 105) . This effect is concentration dependent and the secretory response is associated with a concomitant increase in cytoplasmic calcium concentration. The pattern of calcium fluorescence following phenylalanine exposure is a gradual increase over 20 min, similar to the pattern observed with other secretagogues that open calcium channels (102, 105) . The observation that diltiazem blocks both the phenylalanine-stimulated increase in [Ca 2+ ] i and CCK secretion indicates that the changes in [Ca 2+ ] i are the result of opening of L-type calcium channels. In contrast to glucose, which inhibits 86 Rb efflux, phenylalanine has no effect on 86 Rb efflux, indicating that its activation of calcium channels is not secondary to inhibition of potassium channel activity and depolarization of the plasma membrane. Patch-clamp recordings from cell-attached membrane patches confirm that phenylalanine activates calcium channel activity; however, the exact manner by which phenylalanine causes calcium channel activation and CCK release is unknown (104) . Whether an extracellular site is involved or cotransport of phenylalanine into the cell is required for calcium channel activation will be important areas of future investigation.
Considerable evidence indicates the importance of [Ca 2+ ] i in signaling CCK secretion. First, the calcium channel opener Bay K 8644 was observed to activate calcium channels in STC-1 cells (118) . Second, agents that inhibit K ATP channels (e.g. glucose, disopyramide, phenylalanine), or secretagogues that act through cell surface receptors (e.g. bombesin), all increased [Ca 2+ ] i . Moreover, CCK secretion was induced by these agents and was blocked by the L-type calcium channel blockers diltiazem or nifedipine.
The importance of calcium signaling in CCK secretion led to studies designed to determine its relationship with other second messengers such as cAMP. It had been well documented that CCK release can be stimulated either by agents that elevate intracellular cAMP levels or by treatment with cAMP analogues (95) . However, recently it has become evident in STC-1 cells that CCK secretion induced by cAMP can be blocked by diltiazem. Other evidence invoking an important role for calcium in the cAMP pathway was the observation that elevation of cAMP was associated with an elevation in [Ca 2+ ] i . To examine the mechanism for this effect, the catalytic subunit of PKA was added to the cytoplasmic surface of inside-out membrane patches. Under these conditions, PKA activated calcium channels, suggesting that the effect of cAMP on calcium channel activity was likely through PKA (105) . Therefore, it was extremely interesting when it was found that a selective calcium-calmodulin kinase II (Cam KII) inhibitor blocked the cAMP-mediated increase in [Ca 2+ ] i and inhibited CCK secretion. Together these observations indicate that phosphorylation events mediated by PKA and Cam KII are involved in calcium channel activation by the cAMP second messenger pathway. To date, the electrophysiological events described for CCK secretion can be summarized by the diagram in Figure 5 . Pharmacological, secretory, and electrophysiological studies have shown that potassium channel activity is important for the generation and maintenance of resting membrane potential in CCK-secreting cells. A decrease in potassium conductance, such as that which occurs by closure of K ATP channels (1), causes depolarization of the plasma membrane, which activates voltage-sensitive (L-type) calcium channels (2) . The corresponding increase in [Ca 2+ ] i serves to trigger CCK release (3) and activate a second family of potassium channels (4) . Stimulation of calciumactivated potassium channels serves to hyperpolarize the plasma membrane, thus restoring the basal membrane potential. As shown in the diagram, calcium channels may also be opened by amino acids (e.g. phenylalanine) (5) or through ligand-receptor interactions that couple to the phosphoinositide cascade (e.g. GRP or bombesin) (6) . Increases in cAMP levels, which may occur by other receptor-initiated events, activate calcium channels through interaction of PKA with a channel or a closely associated membrane protein (7) . Cyclic AMP-mediated activation of calcium channels is dependent upon Cam KII, which indicates that at least two phosphorylation events are necessary for cAMP-stimulated activity.
